Tommaso Barba
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Psilocybin's therapeutic potential for various medical conditions is being explored, including pilot studies on Alzheimer's Disease and chronic Lyme Disease. Preliminary results and participant reports inform ongoing psilocybin-assisted treatments research.
Albert Garcia-Romeu
Wellness and Psychedelics: Academic studies show psychedelics, in clinical settings with therapy, rapidly improve psychiatric conditions. Survey of 3,000 adults found significant improvements in mental health with psychedelic use.
Saundra Jain
Overview of a multicenter trial compares psilocybin therapy to active control for demoralization in end-of-life adults. Trial focuses on treating depression, anxiety, and improving quality of life, spiritual well-being, and
Jessi Humphreys
Family involvement in psychedelic therapy can optimize outcomes and prevent problematic patterns. Ethical, neurobiological, and psychological aspects, along with clinical trial data, support the benefits of engaging family members.
Jennifer Danby
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
Psychedelics are studied for psychiatric disorders; research emphasizes 'set and setting.' Study explores psychosocial factors in psychedelic use, linking communal experiences to improved mental health outcomes.
Hannes Kettner
5-MeO-DMT, a natural tryptamine, shows psychedelic effects by acting on serotonin receptors. Clinical trials suggest its potential for rapidly reducing depression symptoms, prompting further studies for depression treatment.
Johannes Reckweg
Four sources of data explore scientific findings on psychedelic-mediated personality change. Results from meta-analytic project, clinical trial, observational findings, and qualitative reports are discussed, along with underlying mechanisms and limitations.
Brandon Weiss
Paul discusses the historical use and potential for neurological health of psilocybin mushrooms, based on his team's molecular research and clinical studies at MycoMedica Life Sciences.
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.